drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01001 | DB09045 | 688 | 52 | [
"DDInter1632",
"DDInter607"
] | Salbutamol | Dulaglutide | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
688,
24,
52
]
],
[
[
688,
24,
170
],
[
170,
23,
52
]
],
[
[
688,
24,
280
],
[
280,
24,
52
]
],
[
[
688,
63,
73
],
[
73,
24,
... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
... | Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Mephentermine and Me... |
DB11827 | DB14730 | 433 | 1,412 | [
"DDInter669",
"DDInter264"
] | Ertugliflozin | Calaspargase pegol | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
433,
24,
1412
]
],
[
[
433,
63,
1144
],
[
1144,
24,
1412
]
],
[
[
433,
24,
1019
],
[
1019,
24,
1412
]
],
[
[
433,
63,
1144
],
[
1144,
... | [
[
[
"Ertugliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Ertugliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
... | Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Defla... |
DB00176 | DB00857 | 529 | 1,387 | [
"DDInter770",
"DDInter1768"
] | Fluvoxamine | Terbinafine | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epox... | Moderate | 1 | [
[
[
529,
24,
1387
]
],
[
[
529,
6,
8374
],
[
8374,
45,
1387
]
],
[
[
529,
18,
3741
],
[
3741,
57,
1387
]
],
[
[
529,
21,
29047
],
[
29047,... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terbinafine"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Fluvoxamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Terbinafine (Compound)
Fluvoxamine (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Terbinafine (Compound)
Fluvoxamine (Compound) causes Hepatic function abnormal (Side Effect) and Hepatic function abnormal (Side Effect) ... |
DB01131 | DB06723 | 1,243 | 115 | [
"DDInter1531",
"DDInter58"
] | Proguanil | Aluminum hydroxide | Proguanil is a prophylactic antimalarial drug, which works by stopping the malaria parasite, _Plasmodium falciparum_ and _Plasmodium vivax_, from reproducing once it is in the red blood cells. It does this by inhibiting the enzyme, dihydrofolate reductase, which is involved in the reproduction of the parasite. | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Moderate | 1 | [
[
[
1243,
24,
115
]
],
[
[
1243,
21,
28882
],
[
28882,
60,
115
]
],
[
[
1243,
63,
954
],
[
954,
23,
115
]
],
[
[
1243,
63,
929
],
[
929,
... | [
[
[
"Proguanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Proguanil",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature incr... | Proguanil (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Aluminum hydroxide (Compound)
Proguanil may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a minor interaction that can limit clin... |
DB00372 | DB11859 | 999 | 418 | [
"DDInter1793",
"DDInter230"
] | Thiethylperazine | Brexanolone | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically for the treatment of postpartum depression (PPD) in adult females . Since PPD, like various other types of depr... | Moderate | 1 | [
[
[
999,
24,
418
]
],
[
[
999,
24,
100
],
[
100,
24,
418
]
],
[
[
999,
63,
1648
],
[
1648,
24,
418
]
],
[
[
999,
25,
593
],
[
593,
2... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramin... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB11703 | DB12095 | 405 | 179 | [
"DDInter9",
"DDInter1760"
] | Acalabrutinib | Telotristat ethyl | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Moderate | 1 | [
[
[
405,
24,
179
]
],
[
[
405,
64,
1213
],
[
1213,
24,
179
]
],
[
[
405,
63,
392
],
[
392,
24,
179
]
],
[
[
405,
25,
283
],
[
283,
6... | [
[
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
... | Acalabrutinib may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib m... |
DB00030 | DB01577 | 1,685 | 1,529 | [
"DDInter934",
"DDInter1161"
] | Insulin human | Metamfetamine | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potentia... | Moderate | 1 | [
[
[
1685,
24,
1529
]
],
[
[
1685,
24,
939
],
[
939,
40,
1529
]
],
[
[
1685,
24,
22
],
[
22,
24,
1529
]
],
[
[
1685,
24,
551
],
[
551,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzphetamine"
... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Benzphetamine and Benzphetamine (Compound) resembles Metamfetamine (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a moderate interacti... |
DB00631 | DB00766 | 372 | 1,675 | [
"DDInter405",
"DDInter394"
] | Clofarabine | Clavulanic acid | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Clavulanic acid is a beta-lactamase inhibitor that is frequently combined with [Amoxicillin] or [Ticarcillin] to fight antibiotic resistance by preventing their degradation by beta-lactamase enzymes, broadening their spectrum of susceptible bacterial infections. Clavulanic acid is derived from the organism Streptomyces... | Moderate | 1 | [
[
[
372,
24,
1675
]
],
[
[
372,
21,
28931
],
[
28931,
60,
1675
]
],
[
[
372,
24,
850
],
[
850,
63,
1675
]
],
[
[
372,
63,
482
],
[
482,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clavulanic acid"
]
],
[
[
"Clofarabine",
"{u} (Compound) causes {v} (Side Effect)",
"Haemorrhage"
],
[
"Haemorrhage",
"{u} (Side Effe... | Clofarabine (Compound) causes Haemorrhage (Side Effect) and Haemorrhage (Side Effect) is caused by Clavulanic acid (Compound)
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate dis... |
DB00771 | DB01192 | 262 | 560 | [
"DDInter397",
"DDInter1372"
] | Clidinium | Oxymorphone | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). O... | Moderate | 1 | [
[
[
262,
24,
560
]
],
[
[
262,
63,
828
],
[
828,
1,
560
]
],
[
[
262,
24,
314
],
[
314,
1,
560
]
],
[
[
262,
24,
1123
],
[
1123,
24,... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxymorphone"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
],
[
... | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) resembles Oxymorphone (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine (Compound) resembles Oxymorphone (Compound)
Cl... |
DB00384 | DB00927 | 1,275 | 1,559 | [
"DDInter1859",
"DDInter712"
] | Triamterene | Famotidine | Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. Since it a... | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Minor | 0 | [
[
[
1275,
23,
1559
]
],
[
[
1275,
21,
28826
],
[
28826,
60,
1559
]
],
[
[
1275,
24,
1274
],
[
1274,
23,
1559
]
],
[
[
1275,
24,
286
],
[
2... | [
[
[
"Triamterene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Famotidine"
]
],
[
[
"Triamterene",
"{u} (Compound) causes {v} (Side Effect)",
"Jaundice"
],
[
"Jaundice",
"{u} (Side Effect) is caused... | Triamterene (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Famotidine (Compound)
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a minor interaction that can limit clinical effects when taken with Famot... |
DB00963 | DB09156 | 1,263 | 777 | [
"DDInter241",
"DDInter964"
] | Bromfenac | Iopromide | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool f... | Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Although iopromide can... | Major | 2 | [
[
[
1263,
25,
777
]
],
[
[
1263,
63,
1512
],
[
1512,
25,
777
]
],
[
[
1263,
24,
712
],
[
712,
25,
777
]
],
[
[
1263,
1,
24
],
[
24,
... | [
[
[
"Bromfenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iopromide"
]
],
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
... | Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Iopromide
Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may lead to a... |
DB01088 | DB01149 | 714 | 851 | [
"DDInter908",
"DDInter1274"
] | Iloprost | Nefazodone | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Moderate | 1 | [
[
[
714,
24,
851
]
],
[
[
714,
63,
274
],
[
274,
24,
851
]
],
[
[
714,
25,
1409
],
[
1409,
63,
851
]
],
[
[
714,
24,
1637
],
[
1637,
... | [
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
],
[
... | Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine and Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone
Iloprost may lead to a major life threatening interaction when taken with Apixaban and Apixaban may cause a mo... |
DB01190 | DB06448 | 568 | 171 | [
"DDInter398",
"DDInter1087"
] | Clindamycin | Lonafarnib | Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms[L11599,L11596] as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bac... | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Moderate | 1 | [
[
[
568,
24,
171
]
],
[
[
568,
24,
129
],
[
129,
64,
171
]
],
[
[
568,
24,
609
],
[
609,
25,
171
]
],
[
[
568,
24,
129
],
[
129,
63,... | [
[
[
"Clindamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Clindamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
... | Clindamycin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Lonafarnib
Clindamycin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromy... |
DB00983 | DB11986 | 480 | 484 | [
"DDInter776",
"DDInter648"
] | Formoterol | Entrectinib | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
480,
24,
484
]
],
[
[
480,
24,
222
],
[
222,
23,
484
]
],
[
[
480,
24,
1539
],
[
1539,
24,
484
]
],
[
[
480,
63,
1674
],
[
1674,
... | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin and Ofloxa... |
DB00454 | DB09098 | 1,349 | 98 | [
"DDInter1150",
"DDInter1700"
] | Meperidine | Somatrem | A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration. | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
1349,
24,
98
]
],
[
[
1349,
24,
159
],
[
159,
63,
98
]
],
[
[
1349,
25,
222
],
[
222,
24,
98
]
],
[
[
1349,
24,
578
],
[
578,
24... | [
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
... | Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Meperidine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may ... |
DB00581 | DB01227 | 355 | 1,301 | [
"DDInter1018",
"DDInter1043"
] | Lactulose | Levacetylmethadol | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Moderate | 1 | [
[
[
355,
24,
1301
]
],
[
[
355,
63,
494
],
[
494,
1,
1301
]
],
[
[
355,
24,
675
],
[
675,
1,
1301
]
],
[
[
355,
24,
657
],
[
657,
63... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyramide"
],
... | Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Levacetylmethadol (Compound)
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene (Compound) resembl... |
DB00323 | DB08880 | 1,062 | 1,510 | [
"DDInter1829",
"DDInter1771"
] | Tolcapone | Teriflunomide | Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity. | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
1062,
25,
1510
]
],
[
[
1062,
23,
126
],
[
126,
24,
1510
]
],
[
[
1062,
24,
850
],
[
850,
25,
1510
]
],
[
[
1062,
25,
1377
],
[
1377,
... | [
[
[
"Tolcapone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Tolcapone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
... | Tolcapone may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Br... |
DB06792 | DB09100 | 1,606 | 320 | [
"DDInter1023",
"DDInter1799"
] | Lanthanum carbonate | Thyroid, porcine | Lanthanum carbonate is a phosphate binder commonly used in clinical practice. It is marketed under the trade name _Fosrenol_ by Shire Pharmaceuticals. It is the largest of all pills filled in community pharmacies. Sometimes patients forget that Fosrenol is not swallowed whole, but instead should be chewed. This has led... | Thyroid extract is dried and powdered thyroid glands from pigs containing tiiodothyronine (T3) and thyroxine (T4) used to supplement low or absent thyroid activity.[A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891 but its use dates back as far as the 6th century. Thyro... | Moderate | 1 | [
[
[
1606,
24,
320
]
],
[
[
1606,
24,
428
],
[
428,
63,
320
]
],
[
[
1606,
63,
1596
],
[
1596,
24,
320
]
],
[
[
1606,
24,
428
],
[
428,
... | [
[
[
"Lanthanum carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Lanthanum carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fer... | Lanthanum carbonate may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Lanthanum carbonate may cause a moderate interaction that could exacerbate diseases w... |
DB00388 | DB01221 | 1,636 | 1,190 | [
"DDInter1453",
"DDInter1007"
] | Phenylephrine | Ketamine | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic... | Moderate | 1 | [
[
[
1636,
24,
1190
]
],
[
[
1636,
21,
28642
],
[
28642,
60,
1190
]
],
[
[
1636,
24,
222
],
[
222,
24,
1190
]
],
[
[
1636,
63,
73
],
[
73,
... | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketamine"
]
],
[
[
"Phenylephrine",
"{u} (Compound) causes {v} (Side Effect)",
"Shock"
],
[
"Shock",
"{u} (Side Effect) is caused b... | Phenylephrine (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Ketamine (Compound)
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Ketamine
... |
DB00637 | DB11718 | 1,557 | 927 | [
"DDInter128",
"DDInter640"
] | Astemizole | Encorafenib | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
1557,
24,
927
]
],
[
[
1557,
23,
112
],
[
112,
23,
927
]
],
[
[
1557,
24,
720
],
[
720,
24,
927
]
],
[
[
1557,
63,
216
],
[
216,
... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Astemizole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Astemizole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mi... |
DB00692 | DB01068 | 274 | 1,565 | [
"DDInter1448",
"DDInter411"
] | Phentolamine | Clonazepam | Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[... | A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechan... | Moderate | 1 | [
[
[
274,
24,
1565
]
],
[
[
274,
63,
1382
],
[
1382,
1,
1565
]
],
[
[
274,
63,
1216
],
[
1216,
40,
1565
]
],
[
[
274,
24,
686
],
[
686,
... | [
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonazepam"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midazolam"
],
[... | Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Midazolam and Midazolam (Compound) resembles Clonazepam (Compound)
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Clonazepam (Compound... |
DB01410 | DB09065 | 423 | 760 | [
"DDInter375",
"DDInter424"
] | Ciclesonide | Cobicistat | Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco. | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
423,
24,
760
]
],
[
[
423,
63,
34
],
[
34,
24,
760
]
],
[
[
423,
40,
167
],
[
167,
24,
760
]
],
[
[
423,
24,
68
],
[
68,
63,
... | [
[
[
"Ciclesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Ciclesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
],
... | Ciclesonide may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir and Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Ciclesonide (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate intera... |
DB00501 | DB14840 | 752 | 861 | [
"DDInter380",
"DDInter1601"
] | Cimetidine | Ripretinib | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA... | Moderate | 1 | [
[
[
752,
24,
861
]
],
[
[
752,
24,
351
],
[
351,
24,
861
]
],
[
[
752,
25,
888
],
[
888,
24,
861
]
],
[
[
752,
62,
1424
],
[
1424,
2... | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
... | Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Cimetidine may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause a ... |
DB00374 | DB06603 | 1,061 | 39 | [
"DDInter1852",
"DDInter1387"
] | Treprostinil | Panobinostat | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
1061,
25,
39
]
],
[
[
1061,
24,
336
],
[
336,
24,
39
]
],
[
[
1061,
24,
578
],
[
578,
63,
39
]
],
[
[
1061,
63,
88
],
[
88,
24,
... | [
[
[
"Treprostinil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
[
"Nife... | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and ... |
DB00476 | DB06704 | 109 | 247 | [
"DDInter608",
"DDInter951"
] | Duloxetine | Iobenguane (I-123) | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Moderate | 1 | [
[
[
109,
37,
247
]
],
[
[
109,
6,
7390
],
[
7390,
45,
247
]
],
[
[
109,
21,
28787
],
[
28787,
60,
247
]
],
[
[
109,
24,
820
],
[
820,
... | [
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Duloxetine",
"{u} (Compound) binds {v} (Gene)",
"SLC6A2... | Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Duloxetine may lead to a major life threatening interaction when taken with Iobenguane
Duloxetine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Iobenguane (Compound)
Duloxetine (Compound) causes Derm... |
DB00270 | DB00586 | 1,428 | 1,512 | [
"DDInter993",
"DDInter537"
] | Isradipine | Diclofenac | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affini... | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Moderate | 1 | [
[
[
1428,
24,
1512
]
],
[
[
1428,
6,
8374
],
[
8374,
45,
1512
]
],
[
[
1428,
21,
29231
],
[
29231,
60,
1512
]
],
[
[
1428,
24,
752
],
[
75... | [
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
]
],
[
[
"Isradipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Isradipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Diclofenac (Compound)
Isradipine (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Diclofenac (Compound)
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Cimet... |
DB08912 | DB09098 | 1,040 | 98 | [
"DDInter462",
"DDInter1700"
] | Dabrafenib | Somatrem | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
1040,
24,
98
]
],
[
[
1040,
23,
1612
],
[
1612,
62,
98
]
],
[
[
1040,
62,
608
],
[
608,
23,
98
]
],
[
[
1040,
63,
671
],
[
671,
... | [
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Dabrafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fostemsavir"
],
[
... | Dabrafenib may cause a minor interaction that can limit clinical effects when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Somatrem
Dabrafenib may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may... |
DB00888 | DB06168 | 1,001 | 1,531 | [
"DDInter1133",
"DDInter281"
] | Mechlorethamine | Canakinumab | A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval f... | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
1001,
24,
1531
]
],
[
[
1001,
63,
1461
],
[
1461,
23,
1531
]
],
[
[
1001,
63,
377
],
[
377,
24,
1531
]
],
[
[
1001,
24,
1270
],
[
1270... | [
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
]... | Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Canakinumab
Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and ... |
DB00211 | DB11963 | 1,290 | 1,045 | [
"DDInter1213",
"DDInter465"
] | Midodrine | Dacomitinib | An ethanolamine derivative that is an adrenergic alpha agonist. It is used as a vasoconstrictor agent in the treatment of hypotension. | Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was devel... | Moderate | 1 | [
[
[
1290,
24,
1045
]
],
[
[
1290,
23,
1194
],
[
1194,
24,
1045
]
],
[
[
1290,
24,
401
],
[
401,
24,
1045
]
],
[
[
1290,
23,
1194
],
[
1194... | [
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacomitinib"
]
],
[
[
"Midodrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ranitidine"
],
[
... | Midodrine may cause a minor interaction that can limit clinical effects when taken with Ranitidine and Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Midodrine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Prometh... |
DB00262 | DB08827 | 552 | 990 | [
"DDInter302",
"DDInter1085"
] | Carmustine | Lomitapide | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Major | 2 | [
[
[
552,
25,
990
]
],
[
[
552,
21,
28658
],
[
28658,
60,
990
]
],
[
[
552,
24,
1362
],
[
1362,
63,
990
]
],
[
[
552,
24,
77
],
[
77,
... | [
[
[
"Carmustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Carmustine",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compou... | Carmustine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Lomitapide (Compound)
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Ca... |
DB11248 | DB14762 | 1,193 | 994 | [
"DDInter1965",
"DDInter1602"
] | Zinc gluconate | Risankizumab | Zinc gluconate is a zinc salt of gluconic acid comprised of two gluconic acid molecules for each zinc cation (2+). Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA. It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and wit... | Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease... | Minor | 0 | [
[
[
1193,
23,
994
]
],
[
[
1193,
62,
58
],
[
58,
24,
994
]
],
[
[
1193,
23,
270
],
[
270,
24,
994
]
],
[
[
1193,
23,
676
],
[
676,
6... | [
[
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Risankizumab"
]
],
[
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Alefacept"
],
... | Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Risankizumab
Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab and O... |
DB00439 | DB05773 | 289 | 1,047 | [
"DDInter341",
"DDInter1848"
] | Cerivastatin | Trastuzumab emtansine | On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Cana... | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Moderate | 1 | [
[
[
289,
24,
1047
]
],
[
[
289,
24,
375
],
[
375,
63,
1047
]
],
[
[
289,
24,
458
],
[
458,
24,
1047
]
],
[
[
289,
63,
1057
],
[
1057,
... | [
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab... | Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Cerivastatin may cause a moderate interaction that could exacerbate diseases when t... |
DB01319 | DB06589 | 34 | 1,250 | [
"DDInter777",
"DDInter1400"
] | Fosamprenavir | Pazopanib | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Major | 2 | [
[
[
34,
25,
1250
]
],
[
[
34,
6,
8374
],
[
8374,
45,
1250
]
],
[
[
34,
21,
29203
],
[
29203,
60,
1250
]
],
[
[
34,
25,
1135
],
[
1135,
... | [
[
[
"Fosamprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
]
],
[
[
"Fosamprenavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Pa... | Fosamprenavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pazopanib (Compound)
Fosamprenavir (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) is caused by Pazopanib (Compound)
Fosamprenavir may lead to a major life threatening i... |
DB01263 | DB12001 | 859 | 564 | [
"DDInter1494",
"DDInter7"
] | Posaconazole | Abemaciclib | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Major | 2 | [
[
[
859,
25,
564
]
],
[
[
859,
25,
868
],
[
868,
24,
564
]
],
[
[
859,
64,
392
],
[
392,
24,
564
]
],
[
[
859,
63,
600
],
[
600,
24,... | [
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
]
],
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
... | Posaconazole may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Posaconazole may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate... |
DB00468 | DB01591 | 1,424 | 667 | [
"DDInter1557",
"DDInter1696"
] | Quinine | Solifenacin | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
1424,
24,
667
]
],
[
[
1424,
6,
4304
],
[
4304,
45,
667
]
],
[
[
1424,
21,
29426
],
[
29426,
60,
667
]
],
[
[
1424,
23,
112
],
[
112,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Quinine",
"{u} (Compound) binds {v} (Gene)",
"CHRM2"
],
[
"CHRM2",
"{u} (Gene) is bound by {v} (Compound)",
... | Quinine (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Solifenacin (Compound)
Quinine (Compound) causes Torsade de pointes (Side Effect) and Torsade de pointes (Side Effect) is caused by Solifenacin (Compound)
Quinine may cause a minor interaction that can limit clinical effects when taken with Metronidazol... |
DB00295 | DB00758 | 475 | 1,347 | [
"DDInter1244",
"DDInter413"
] | Morphine | Clopidogrel | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Moderate | 1 | [
[
[
475,
24,
1347
]
],
[
[
475,
10,
11576
],
[
11576,
44,
1347
]
],
[
[
475,
6,
3486
],
[
3486,
45,
1347
]
],
[
[
475,
21,
29402
],
[
2940... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
]
],
[
[
"Morphine",
"{u} (Compound) palliates {v} (Disease)",
"coronary artery disease"
],
[
"coronary artery disease",
"{... | Morphine (Compound) palliates coronary artery disease (Disease) and coronary artery disease (Disease) is treated by Clopidogrel (Compound)
Morphine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Clopidogrel (Compound)
Morphine (Compound) causes Hepatobiliary disease (Side Effect) and Hepatobiliary disease... |
DB00586 | DB00999 | 1,512 | 504 | [
"DDInter537",
"DDInter883"
] | Diclofenac | Hydrochlorothiazide | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and a... | Moderate | 1 | [
[
[
1512,
24,
504
]
],
[
[
1512,
24,
178
],
[
178,
1,
504
]
],
[
[
1512,
63,
323
],
[
323,
40,
504
]
],
[
[
1512,
24,
359
],
[
359,
... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
... | Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polythiazide (Compound) resembles Hydrochlorothiazide (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Bendroflumethiazide and Bendroflumethiazide (Compound) r... |
DB00585 | DB09104 | 1,127 | 286 | [
"DDInter1309",
"DDInter1118"
] | Nizatidine | Magnesium hydroxide | A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers. | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Minor | 0 | [
[
[
1127,
23,
286
]
],
[
[
1127,
62,
109
],
[
109,
23,
286
]
],
[
[
1127,
1,
1194
],
[
1194,
23,
286
]
],
[
[
1127,
23,
263
],
[
263,
... | [
[
[
"Nizatidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Nizatidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Duloxetine"
],
... | Nizatidine may cause a minor interaction that can limit clinical effects when taken with Duloxetine and Duloxetine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Nizatidine (Compound) resembles Ranitidine (Compound) and Ranitidine may cause a minor interaction that can... |
DB00434 | DB11859 | 13 | 418 | [
"DDInter459",
"DDInter230"
] | Cyproheptadine | Brexanolone | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically for the treatment of postpartum depression (PPD) in adult females . Since PPD, like various other types of depr... | Moderate | 1 | [
[
[
13,
24,
418
]
],
[
[
13,
24,
820
],
[
820,
24,
418
]
],
[
[
13,
63,
1233
],
[
1233,
24,
418
]
],
[
[
13,
24,
820
],
[
820,
63,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]... | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Triprolidi... |
DB00959 | DB01174 | 1,486 | 697 | [
"DDInter1191",
"DDInter1442"
] | Methylprednisolone | Phenobarbital | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Moderate | 1 | [
[
[
1486,
24,
697
]
],
[
[
1486,
63,
759
],
[
759,
1,
697
]
],
[
[
1486,
63,
536
],
[
536,
40,
697
]
],
[
[
1486,
6,
8374
],
[
8374,
... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidon... | Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Phenobarbital (Compound)
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital (Compound) resembles P... |
DB08827 | DB08882 | 990 | 1,281 | [
"DDInter1085",
"DDInter1070"
] | Lomitapide | Linagliptin | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
990,
24,
1281
]
],
[
[
990,
6,
8374
],
[
8374,
45,
1281
]
],
[
[
990,
21,
28729
],
[
28729,
60,
1281
]
],
[
[
990,
25,
1320
],
[
1320,... | [
[
[
"Lomitapide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Lomitapide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Lomitapide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound)
Lomitapide (Compound) causes Pain in extremity (Side Effect) and Pain in extremity (Side Effect) is caused by Linagliptin (Compound)
Lomitapide may lead to a major life threatening interaction when taken with Elagolix and Ela... |
DB00302 | DB08816 | 335 | 578 | [
"DDInter1844",
"DDInter1802"
] | Tranexamic acid | Ticagrelor | Tranexamic acid is a synthetic derivative of [lysine] used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent. It was first patented in 1957 and received its initial US approval in 1986. | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Minor | 0 | [
[
[
335,
23,
578
]
],
[
[
335,
21,
28762
],
[
28762,
60,
578
]
],
[
[
335,
25,
566
],
[
566,
23,
578
]
],
[
[
335,
63,
1255
],
[
1255,
... | [
[
[
"Tranexamic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
]
],
[
[
"Tranexamic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) i... | Tranexamic acid (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ticagrelor (Compound)
Tranexamic acid may lead to a major life threatening interaction when taken with Levonorgestrel and Levonorgestrel may cause a minor interaction that can limit clinical effects when taken with Ticagrel... |
DB00307 | DB06168 | 1,101 | 1,531 | [
"DDInter202",
"DDInter281"
] | Bexarotene | Canakinumab | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
1101,
24,
1531
]
],
[
[
1101,
24,
523
],
[
523,
24,
1531
]
],
[
[
1101,
24,
1270
],
[
1270,
63,
1531
]
],
[
[
1101,
25,
873
],
[
873,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alprazolam"
],
[
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified ... |
DB00421 | DB00860 | 443 | 891 | [
"DDInter1707",
"DDInter1513"
] | Spironolactone | Prednisolone | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were disco... | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Moderate | 1 | [
[
[
443,
24,
891
]
],
[
[
443,
1,
11347
],
[
11347,
40,
891
]
],
[
[
443,
40,
989
],
[
989,
1,
891
]
],
[
[
443,
24,
175
],
[
175,
4... | [
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Spironolactone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortamate"
],
[
"Hydrocortamate",
"{u} (... | Spironolactone (Compound) resembles Hydrocortamate (Compound) and Hydrocortamate (Compound) resembles Prednisolone (Compound)
Spironolactone (Compound) resembles Progesterone (Compound) and Progesterone (Compound) resembles Prednisolone (Compound)
Spironolactone may cause a moderate interaction that could exacerbate di... |
DB00586 | DB12364 | 1,512 | 1,421 | [
"DDInter537",
"DDInter200"
] | Diclofenac | Betrixaban | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Major | 2 | [
[
[
1512,
25,
1421
]
],
[
[
1512,
23,
297
],
[
297,
23,
1421
]
],
[
[
1512,
24,
1017
],
[
1017,
24,
1421
]
],
[
[
1512,
63,
529
],
[
529,
... | [
[
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Diclofenac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u... | Diclofenac may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Betrixaban
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause... |
DB00461 | DB01099 | 598 | 1,272 | [
"DDInter1254",
"DDInter744"
] | Nabumetone | Flucytosine | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | A fluorinated cytosine analog that is used as an antifungal agent. | Moderate | 1 | [
[
[
598,
24,
1272
]
],
[
[
598,
21,
29209
],
[
29209,
60,
1272
]
],
[
[
598,
24,
1448
],
[
1448,
24,
1272
]
],
[
[
598,
24,
712
],
[
712,
... | [
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flucytosine"
]
],
[
[
"Nabumetone",
"{u} (Compound) causes {v} (Side Effect)",
"Anorexia"
],
[
"Anorexia",
"{u} (Side Effect) is cause... | Nabumetone (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Flucytosine (Compound)
Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Fluc... |
DB00544 | DB01320 | 970 | 651 | [
"DDInter757",
"DDInter783"
] | Fluorouracil | Fosphenytoin | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Moderate | 1 | [
[
[
970,
24,
651
]
],
[
[
970,
63,
362
],
[
362,
1,
651
]
],
[
[
970,
6,
6017
],
[
6017,
45,
651
]
],
[
[
970,
21,
29028
],
[
29028,
... | [
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
... | Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Fluorouracil (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Fosphenytoin (Compound)
Fluorouracil (Compound) causes Encephalopathy (Side Effect) ... |
DB00619 | DB06702 | 1,419 | 573 | [
"DDInter909",
"DDInter731"
] | Imatinib | Fesoterodine | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Moderate | 1 | [
[
[
1419,
24,
573
]
],
[
[
1419,
24,
211
],
[
211,
1,
573
]
],
[
[
1419,
63,
494
],
[
494,
1,
573
]
],
[
[
1419,
6,
12523
],
[
12523,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
[
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Fesoterodine (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Fesoterodine (Comp... |
DB00662 | DB01142 | 717 | 1,264 | [
"DDInter1873",
"DDInter593"
] | Trimethobenzamide | Doxepin | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
717,
24,
1264
]
],
[
[
717,
63,
508
],
[
508,
24,
1264
]
],
[
[
717,
24,
401
],
[
401,
24,
1264
]
],
[
[
717,
24,
649
],
[
649,
... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
]... | Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine... |
DB01035 | DB09076 | 1,401 | 1,116 | [
"DDInter1524",
"DDInter1899"
] | Procainamide | Umeclidinium | A derivative of procaine with less CNS action. | Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory vo... | Moderate | 1 | [
[
[
1401,
24,
1116
]
],
[
[
1401,
24,
1429
],
[
1429,
24,
1116
]
],
[
[
1401,
25,
401
],
[
401,
24,
1116
]
],
[
[
1401,
63,
352
],
[
352,
... | [
[
[
"Procainamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
],
[
[
"Procainamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aclidinium"
],
... | Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium and Aclidinium may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Procainamide may lead to a major life threatening interaction when taken with Promethazine and Promethazine ... |
DB00087 | DB00563 | 599 | 663 | [
"DDInter41",
"DDInter1174"
] | Alemtuzumab | Methotrexate | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Moderate | 1 | [
[
[
599,
24,
663
]
],
[
[
599,
24,
328
],
[
328,
62,
663
]
],
[
[
599,
24,
157
],
[
157,
63,
663
]
],
[
[
599,
63,
1648
],
[
1648,
2... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
],
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a minor interaction that can limit clinical effects when taken with Methotrexate
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Ethotoin an... |
DB01075 | DB09076 | 1,376 | 1,116 | [
"DDInter569",
"DDInter1899"
] | Diphenhydramine | Umeclidinium | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory vo... | Moderate | 1 | [
[
[
1376,
24,
1116
]
],
[
[
1376,
24,
849
],
[
849,
24,
1116
]
],
[
[
1376,
63,
1300
],
[
1300,
24,
1116
]
],
[
[
1376,
35,
358
],
[
358,
... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
... | Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Haloperid... |
DB11652 | DB11703 | 1,155 | 405 | [
"DDInter1891",
"DDInter9"
] | Tucatinib | Acalabrutinib | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
1155,
25,
405
]
],
[
[
1155,
63,
1051
],
[
1051,
24,
405
]
],
[
[
1155,
62,
1101
],
[
1101,
24,
405
]
],
[
[
1155,
64,
951
],
[
951,
... | [
[
[
"Tucatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Tucatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
],
[
"Am... | Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Tucatinib may cause a minor interaction that can limit clinical effects when taken with Bexarote... |
DB01208 | DB01234 | 945 | 1,220 | [
"DDInter1705",
"DDInter513"
] | Sparfloxacin | Dexamethasone | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Major | 2 | [
[
[
945,
25,
1220
]
],
[
[
945,
64,
870
],
[
870,
1,
1220
]
],
[
[
945,
64,
175
],
[
175,
40,
1220
]
],
[
[
945,
6,
4973
],
[
4973,
... | [
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
]
],
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortiso... | Sparfloxacin may lead to a major life threatening interaction when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Sparfloxacin may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexamethasone (Compound)
Spar... |
DB01233 | DB11160 | 1,311 | 337 | [
"DDInter1197",
"DDInter1459"
] | Metoclopramide | Phenyltoloxamine | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Phenyltoloxamine is an antihistamine drug with sedative and analgesic effects. It is a H1 receptor blocker and a member of the ethanolamine class of antihistaminergic drugs. It is available in combination products that also contain other analgesics and antitussives such as acetaminophen. Phenyltoloxamine citrate is the... | Moderate | 1 | [
[
[
1311,
24,
337
]
],
[
[
1311,
25,
820
],
[
820,
24,
337
]
],
[
[
1311,
64,
999
],
[
999,
24,
337
]
],
[
[
1311,
63,
1594
],
[
1594,
... | [
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Metoclopramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alimemazine"
],
[
... | Metoclopramide may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine
Metoclopramide may lead to a major life threatening interaction when taken with Thiethylperazine and Thiethylperazi... |
DB00631 | DB10316 | 372 | 334 | [
"DDInter405",
"DDInter1248"
] | Clofarabine | Mumps virus strain B level jeryl lynn live antigen | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Major | 2 | [
[
[
372,
25,
334
]
],
[
[
372,
24,
594
],
[
594,
25,
334
]
],
[
[
372,
64,
1057
],
[
1057,
25,
334
]
],
[
[
372,
25,
908
],
[
908,
2... | [
[
[
"Clofarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Clofarabine may lead to a major life threatening interaction when taken with Etanercept ... |
DB06168 | DB13007 | 1,531 | 1,060 | [
"DDInter281",
"DDInter642"
] | Canakinumab | Enfortumab vedotin | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Moderate | 1 | [
[
[
1531,
24,
1060
]
],
[
[
1531,
24,
270
],
[
270,
24,
1060
]
],
[
[
1531,
63,
58
],
[
58,
24,
1060
]
],
[
[
1531,
25,
980
],
[
980,
... | [
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
... | Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept... |
DB00604 | DB00983 | 1,425 | 480 | [
"DDInter385",
"DDInter776"
] | Cisapride | Formoterol | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Moderate | 1 | [
[
[
1425,
24,
480
]
],
[
[
1425,
25,
1148
],
[
1148,
63,
480
]
],
[
[
1425,
6,
8717
],
[
8717,
45,
480
]
],
[
[
1425,
25,
932
],
[
932,
... | [
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isoprenaline"
],
[
"Isoprenali... | Cisapride may lead to a major life threatening interaction when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Cisapride (Compound) binds CYP2A6 (Gene) and CYP2A6 (Gene) is bound by Formoterol (Compound)
Cisapride may lead to a major l... |
DB00472 | DB09078 | 758 | 1,228 | [
"DDInter758",
"DDInter1036"
] | Fluoxetine | Lenvatinib | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
758,
24,
1228
]
],
[
[
758,
23,
112
],
[
112,
23,
1228
]
],
[
[
758,
24,
609
],
[
609,
24,
1228
]
],
[
[
758,
25,
1264
],
[
1264,
... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Fluoxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Fluoxetine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and ... |
DB00104 | DB12095 | 966 | 179 | [
"DDInter1323",
"DDInter1760"
] | Octreotide | Telotristat ethyl | Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may... | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Major | 2 | [
[
[
966,
25,
179
]
],
[
[
966,
24,
761
],
[
761,
24,
179
]
],
[
[
966,
24,
877
],
[
877,
63,
179
]
],
[
[
966,
25,
1101
],
[
1101,
2... | [
[
[
"Octreotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Sa... | Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin ... |
DB00397 | DB01064 | 1,466 | 1,148 | [
"DDInter1458",
"DDInter987"
] | Phenylpropanolamine | Isoprenaline | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Moderate | 1 | [
[
[
1466,
24,
1148
]
],
[
[
1466,
63,
1636
],
[
1636,
24,
1148
]
],
[
[
1466,
24,
480
],
[
480,
24,
1148
]
],
[
[
1466,
35,
584
],
[
584,
... | [
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyle... | Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00598 | DB09080 | 1,523 | 144 | [
"DDInter1013",
"DDInter1331"
] | Labetalol | Olodaterol | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Major | 2 | [
[
[
1523,
25,
144
]
],
[
[
1523,
40,
371
],
[
371,
24,
144
]
],
[
[
1523,
25,
1011
],
[
1011,
24,
144
]
],
[
[
1523,
24,
1445
],
[
1445,
... | [
[
[
"Labetalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olodaterol"
]
],
[
[
"Labetalol",
"{u} (Compound) resembles {v} (Compound)",
"Propafenone"
],
[
"Propafenone",
"{u} may cause a moderate interaction t... | Labetalol (Compound) resembles Propafenone (Compound) and Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Labetalol may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate dis... |
DB00363 | DB01169 | 695 | 57 | [
"DDInter419",
"DDInter120"
] | Clozapine | Arsenic trioxide | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Major | 2 | [
[
[
695,
25,
57
]
],
[
[
695,
6,
8374
],
[
8374,
45,
57
]
],
[
[
695,
23,
112
],
[
112,
23,
57
]
],
[
[
695,
24,
603
],
[
603,
63,
... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Clozapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ars... | Clozapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Arsenic trioxide (Compound)
Clozapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Arsenic trioxide
Clozap... |
DB00095 | DB08879 | 66 | 632 | [
"DDInter623",
"DDInter173"
] | Efalizumab | Belimumab | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Belimumab is a fully human recombinant IgG1λ monoclonal antibody that inhibits soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B cell survival factor. BLyS levels are often elevated in immunodeficient and autoimmune disorders, such as systemic lupus erythematosus (SLE).[A2... | Moderate | 1 | [
[
[
66,
24,
632
]
],
[
[
66,
23,
1461
],
[
1461,
23,
632
]
],
[
[
66,
23,
1114
],
[
1114,
62,
632
]
],
[
[
66,
24,
713
],
[
713,
63,... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belimumab"
]
],
[
[
"Efalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
... | Efalizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Belimumab
Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate ... |
DB06636 | DB12364 | 1,623 | 1,421 | [
"DDInter980",
"DDInter200"
] | Isavuconazonium | Betrixaban | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Moderate | 1 | [
[
[
1623,
24,
1421
]
],
[
[
1623,
63,
1513
],
[
1513,
24,
1421
]
],
[
[
1623,
24,
1017
],
[
1017,
24,
1421
]
],
[
[
1623,
25,
1406
],
[
14... | [
[
[
"Isavuconazonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Isavuconazonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apremilast"
]... | Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Apremilast and Apremilast may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib ... |
DB00108 | DB11952 | 1,066 | 800 | [
"DDInter1268",
"DDInter612"
] | Natalizumab | Duvelisib | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Major | 2 | [
[
[
1066,
25,
800
]
],
[
[
1066,
25,
310
],
[
310,
24,
800
]
],
[
[
1066,
25,
1476
],
[
1476,
63,
800
]
],
[
[
1066,
24,
267
],
[
267,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duvelisib"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u... | Natalizumab may lead to a major life threatening interaction when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Natalizumab may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate i... |
DB00436 | DB00620 | 323 | 175 | [
"DDInter179",
"DDInter1855"
] | Bendroflumethiazide | Triamcinolone | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Moderate | 1 | [
[
[
323,
24,
175
]
],
[
[
323,
24,
1573
],
[
1573,
1,
175
]
],
[
[
323,
63,
218
],
[
218,
1,
175
]
],
[
[
323,
21,
28722
],
[
28722,
... | [
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Predni... | Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) resembles Triamcinolone (Compound)
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Beclomethasone dipropionate and Beclomethasone d... |
DB00771 | DB00835 | 262 | 100 | [
"DDInter397",
"DDInter245"
] | Clidinium | Brompheniramine | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
262,
24,
100
]
],
[
[
262,
24,
832
],
[
832,
24,
100
]
],
[
[
262,
63,
508
],
[
508,
24,
100
]
],
[
[
262,
24,
211
],
[
211,
63,... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
... | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Promazine ... |
DB00834 | DB12010 | 932 | 214 | [
"DDInter1215",
"DDInter785"
] | Mifepristone | Fostamatinib | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
932,
24,
214
]
],
[
[
932,
24,
976
],
[
976,
24,
214
]
],
[
[
932,
63,
723
],
[
723,
24,
214
]
],
[
[
932,
25,
866
],
[
866,
24,... | [
[
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
... | Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant an... |
DB00018 | DB11988 | 199 | 270 | [
"DDInter945",
"DDInter1321"
] | Interferon alfa-n3 | Ocrelizumab | Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD). | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
199,
24,
270
]
],
[
[
199,
23,
450
],
[
450,
24,
270
]
],
[
[
199,
25,
1648
],
[
1648,
24,
270
]
],
[
[
199,
24,
4
],
[
4,
24,
... | [
[
[
"Interferon alfa-n3",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Interferon alfa-n3",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cyclophospha... | Interferon alfa-n3 may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Interferon alfa-n3 may lead to a major life threatening interaction when taken with Aldesleuk... |
DB00204 | DB00938 | 228 | 455 | [
"DDInter580",
"DDInter1635"
] | Dofetilide | Salmeterol | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
228,
24,
455
]
],
[
[
228,
24,
688
],
[
688,
63,
455
]
],
[
[
228,
6,
8374
],
[
8374,
45,
455
]
],
[
[
228,
21,
29024
],
[
29024,
... | [
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
... | Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Dofetilide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Salmeterol (Compound)
Dofetilide (Compou... |
DB00651 | DB01136 | 746 | 772 | [
"DDInter613",
"DDInter305"
] | Dyphylline | Carvedilol | Dyphylline is a theophylline derivative with broncho- and vasodilator properties. It is typically used in the management of asthma, cardiac dyspnea, and bronchitis. | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Major | 2 | [
[
[
746,
25,
772
]
],
[
[
746,
21,
29118
],
[
29118,
60,
772
]
],
[
[
746,
23,
22
],
[
22,
63,
772
]
],
[
[
746,
24,
1148
],
[
1148,
... | [
[
[
"Dyphylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carvedilol"
]
],
[
[
"Dyphylline",
"{u} (Compound) causes {v} (Side Effect)",
"Tachycardia"
],
[
"Tachycardia",
"{u} (Side Effect) is caused by {v} (... | Dyphylline (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Carvedilol (Compound)
Dyphylline may cause a minor interaction that can limit clinical effects when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Carvedi... |
DB01097 | DB11730 | 1,377 | 351 | [
"DDInter1033",
"DDInter1588"
] | Leflunomide | Ribociclib | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
1377,
25,
351
]
],
[
[
1377,
63,
112
],
[
112,
23,
351
]
],
[
[
1377,
25,
283
],
[
283,
62,
351
]
],
[
[
1377,
25,
1627
],
[
1627,
... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metro... | Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Leflunomide may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may ... |
DB00065 | DB12893 | 581 | 586 | [
"DDInter923",
"DDInter1629"
] | Infliximab | Sacituzumab govitecan | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. One such ADC is sacituzumab goviteca... | Major | 2 | [
[
[
581,
25,
586
]
],
[
[
581,
25,
270
],
[
270,
24,
586
]
],
[
[
581,
24,
58
],
[
58,
24,
586
]
],
[
[
581,
64,
1184
],
[
1184,
24,... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sacituzumab govitecan"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",... | Infliximab may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Sacituzumab govitecan
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept... |
DB00176 | DB09564 | 529 | 1,296 | [
"DDInter770",
"DDInter930"
] | Fluvoxamine | Insulin degludec | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
529,
24,
1296
]
],
[
[
529,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
529,
25,
73
],
[
73,
24,
1296
]
],
[
[
529,
24,
1476
],
[
1476,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],... | Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Fluvoxamine may lead to a major life threatening interaction when taken with Phentermine and Phentermin... |
DB01124 | DB02546 | 1,411 | 137 | [
"DDInter1828",
"DDInter1947"
] | Tolbutamide | Vorinostat | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new clas... | Moderate | 1 | [
[
[
1411,
24,
137
]
],
[
[
1411,
18,
5818
],
[
5818,
46,
137
]
],
[
[
1411,
7,
10809
],
[
10809,
46,
137
]
],
[
[
1411,
18,
3390
],
[
3390... | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorinostat"
]
],
[
[
"Tolbutamide",
"{u} (Compound) downregulates {v} (Gene)",
"ATP6V0B"
],
[
"ATP6V0B",
"{u} (Gene) is upregulated b... | Tolbutamide (Compound) downregulates ATP6V0B (Gene) and ATP6V0B (Gene) is upregulated by Vorinostat (Compound)
Tolbutamide (Compound) upregulates RBKS (Gene) and RBKS (Gene) is upregulated by Vorinostat (Compound)
Tolbutamide (Compound) downregulates RPN1 (Gene) and RPN1 (Gene) is downregulated by Vorinostat (Compound)... |
DB00333 | DB00574 | 576 | 121 | [
"DDInter1166",
"DDInter717"
] | Methadone | Fenfluramine | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Moderate | 1 | [
[
[
576,
24,
121
]
],
[
[
576,
24,
173
],
[
173,
62,
121
]
],
[
[
576,
25,
868
],
[
868,
63,
121
]
],
[
[
576,
24,
659
],
[
659,
63,... | [
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
]
],
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxone"
],
[
... | Methadone may cause a moderate interaction that could exacerbate diseases when taken with Naloxone and Naloxone may cause a minor interaction that can limit clinical effects when taken with Fenfluramine
Methadone may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a mo... |
DB05528 | DB09570 | 1,070 | 1,480 | [
"DDInter1228",
"DDInter1002"
] | Mipomersen | Ixazomib | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. M... | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Major | 2 | [
[
[
1070,
25,
1480
]
],
[
[
1070,
64,
268
],
[
268,
24,
1480
]
],
[
[
1070,
25,
214
],
[
214,
63,
1480
]
],
[
[
1070,
25,
1047
],
[
1047,
... | [
[
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixazomib"
]
],
[
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Peginterferon alfa-2b"
],
[
"Peginterferon al... | Mipomersen may lead to a major life threatening interaction when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Mipomersen may lead to a major life threatening interaction when taken with Fostamatinib and Fostamatinib m... |
DB00279 | DB00794 | 1,152 | 759 | [
"DDInter1074",
"DDInter1521"
] | Liothyronine | Primidone | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Moderate | 1 | [
[
[
1152,
24,
759
]
],
[
[
1152,
24,
697
],
[
697,
40,
759
]
],
[
[
1152,
63,
362
],
[
362,
1,
759
]
],
[
[
1152,
24,
761
],
[
761,
... | [
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
... | Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital (Compound) resembles Primidone (Compound)
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Primidone (Comp... |
DB00792 | DB00831 | 832 | 1,178 | [
"DDInter1878",
"DDInter1866"
] | Tripelennamine | Trifluoperazine | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Moderate | 1 | [
[
[
832,
24,
1178
]
],
[
[
832,
63,
695
],
[
695,
40,
1178
]
],
[
[
832,
24,
851
],
[
851,
40,
1178
]
],
[
[
832,
24,
1630
],
[
1630,
... | [
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
... | Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine (Compound) resembles Trifluoperazine (Compound)
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone (Compound) resembles Trifluopera... |
DB00800 | DB01222 | 572 | 617 | [
"DDInter720",
"DDInter246"
] | Fenoldopam | Budesonide | A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation. | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Moderate | 1 | [
[
[
572,
24,
617
]
],
[
[
572,
63,
251
],
[
251,
1,
617
]
],
[
[
572,
24,
1220
],
[
1220,
1,
617
]
],
[
[
572,
21,
28647
],
[
28647,
... | [
[
[
"Fenoldopam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Fenoldopam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[... | Fenoldopam may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Budesonide (Compound)
Fenoldopam may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Budesonide... |
DB01041 | DB06699 | 770 | 774 | [
"DDInter1789",
"DDInter493"
] | Thalidomide | Degarelix | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Moderate | 1 | [
[
[
770,
24,
774
]
],
[
[
770,
63,
521
],
[
521,
1,
774
]
],
[
[
770,
21,
29232
],
[
29232,
60,
774
]
],
[
[
770,
63,
112
],
[
112,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Thalidomide (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Degarelix (Compound)
Thalidomide may cause a moderate interaction t... |
DB01177 | DB11901 | 77 | 913 | [
"DDInter904",
"DDInter107"
] | Idarubicin | Apalutamide | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
77,
24,
913
]
],
[
[
77,
62,
112
],
[
112,
23,
913
]
],
[
[
77,
63,
600
],
[
600,
24,
913
]
],
[
[
77,
24,
1237
],
[
1237,
24,
... | [
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Idarubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Idarubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fl... |
DB00526 | DB01001 | 1,555 | 688 | [
"DDInter1355",
"DDInter1632"
] | Oxaliplatin | Salbutamol | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Moderate | 1 | [
[
[
1555,
24,
688
]
],
[
[
1555,
24,
455
],
[
455,
24,
688
]
],
[
[
1555,
24,
1148
],
[
1148,
63,
688
]
],
[
[
1555,
23,
1247
],
[
1247,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Is... |
DB06317 | DB08827 | 1,626 | 990 | [
"DDInter630",
"DDInter1085"
] | Elotuzumab | Lomitapide | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Major | 2 | [
[
[
1626,
25,
990
]
],
[
[
1626,
63,
973
],
[
973,
24,
990
]
],
[
[
1626,
24,
1362
],
[
1362,
63,
990
]
],
[
[
1626,
24,
310
],
[
310,
... | [
[
[
"Elotuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Elotuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel... | Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib... |
DB01125 | DB01284 | 279 | 1,042 | [
"DDInter98",
"DDInter1782"
] | Anisindione | Tetracosactide | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagu... | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Moderate | 1 | [
[
[
279,
24,
1042
]
],
[
[
279,
24,
123
],
[
123,
24,
1042
]
],
[
[
279,
62,
1647
],
[
1647,
24,
1042
]
],
[
[
279,
63,
1411
],
[
1411,
... | [
[
[
"Anisindione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Anisindione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
],
... | Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Anisindione may cause a minor interaction that can limit clinical effects when taken with Acarbose and Acarbo... |
DB00039 | DB09559 | 1,253 | 432 | [
"DDInter1380",
"DDInter1272"
] | Palifermin | Necitumumab | Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004. | Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, m... | Moderate | 1 | [
[
[
1253,
24,
432
]
],
[
[
1253,
24,
770
],
[
770,
25,
432
]
],
[
[
1253,
24,
1618
],
[
1618,
24,
384
],
[
384,
24,
432
]
],
[
[
1253,
... | [
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Necitumumab"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
... | Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Necitumumab
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib and Cabozantinib may... |
DB00227 | DB04868 | 1,463 | 478 | [
"DDInter1098",
"DDInter1293"
] | Lovastatin | Nilotinib | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disea... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
1463,
24,
478
]
],
[
[
1463,
24,
1468
],
[
1468,
63,
478
]
],
[
[
1463,
6,
6017
],
[
6017,
45,
478
]
],
[
[
1463,
7,
6717
],
[
6717,
... | [
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
... | Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Lovastatin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Lovastatin (Compound) ... |
DB06802 | DB11703 | 282 | 405 | [
"DDInter1280",
"DDInter9"
] | Nepafenac (ophthalmic) | Acalabrutinib | Nepafenac is a monocarboxylic acid amide that is amfenac in which the carboxylic acid group has been converted into the corresponding carboxamide. It is a prodrug for amfenac, used in eye drops to treat pain and inflammation following cataract surgery. It has a role as a prodrug, a cyclooxygenase 2 inhibitor, a cycloox... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
282,
24,
405
]
],
[
[
282,
40,
307
],
[
307,
24,
405
]
],
[
[
282,
1,
1335
],
[
1335,
24,
405
]
],
[
[
282,
63,
1172
],
[
1172,
... | [
[
[
"Nepafenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Nepafenac",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a moderate... | Nepafenac may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Nepafenac (Compound) resembles Modafinil (Compound) and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Nepafenac (Compound) resembles Oxcarbazepine (Compound) ... |
DB00544 | DB01610 | 970 | 248 | [
"DDInter757",
"DDInter1912"
] | Fluorouracil | Valganciclovir | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Moderate | 1 | [
[
[
970,
24,
248
]
],
[
[
970,
24,
563
],
[
563,
1,
248
]
],
[
[
970,
21,
29209
],
[
29209,
60,
248
]
],
[
[
970,
24,
1238
],
[
1238,
... | [
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],... | Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) resembles Valganciclovir (Compound)
Fluorouracil (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Valganciclovir (Compound)
Fluorouracil may cause a moderat... |
DB01076 | DB11730 | 700 | 351 | [
"DDInter133",
"DDInter1588"
] | Atorvastatin | Ribociclib | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competi... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
700,
24,
351
]
],
[
[
700,
24,
466
],
[
466,
62,
351
]
],
[
[
700,
63,
112
],
[
112,
23,
351
]
],
[
[
700,
24,
310
],
[
310,
24,... | [
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
... | Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole a... |
DB00976 | DB09268 | 1,056 | 1,662 | [
"DDInter1758",
"DDInter1464"
] | Telithromycin | Picosulfuric acid | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
1056,
24,
1662
]
],
[
[
1056,
25,
484
],
[
484,
63,
1662
]
],
[
[
1056,
24,
1619
],
[
1619,
63,
1662
]
],
[
[
1056,
25,
1618
],
[
1618... | [
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
],
[
... | Telithromycin may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucapar... |
DB00620 | DB00951 | 175 | 1,072 | [
"DDInter1855",
"DDInter986"
] | Triamcinolone | Isoniazid | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Minor | 0 | [
[
[
175,
23,
1072
]
],
[
[
175,
6,
8374
],
[
8374,
45,
1072
]
],
[
[
175,
21,
28722
],
[
28722,
60,
1072
]
],
[
[
175,
40,
1486
],
[
1486,... | [
[
[
"Triamcinolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Isoniazid"
]
],
[
[
"Triamcinolone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Triamcinolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Isoniazid (Compound)
Triamcinolone (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Isoniazid (Compound)
Triamcinolone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may cause a minor intera... |
DB11601 | DB11703 | 1,270 | 405 | [
"DDInter1889",
"DDInter9"
] | Tuberculin purified protein derivative | Acalabrutinib | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
1270,
24,
405
]
],
[
[
1270,
63,
58
],
[
58,
24,
405
]
],
[
[
1270,
24,
1619
],
[
1619,
63,
405
]
],
[
[
1270,
63,
384
],
[
384,
... | [
[
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseas... | Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Tuberculin purified protein derivative may cause a moderate interaction that could ... |
DB00363 | DB08824 | 695 | 591 | [
"DDInter419",
"DDInter959"
] | Clozapine | Ioflupane I-123 | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Ioflupane (I-123) is a radiopharmaceutical used to image dopamine neurons and diagnose Parkinsonian syndromes. | Moderate | 1 | [
[
[
695,
24,
591
]
],
[
[
695,
40,
1408
],
[
1408,
24,
591
]
],
[
[
695,
24,
401
],
[
401,
24,
591
]
],
[
[
695,
1,
623
],
[
623,
24... | [
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
]
],
[
[
"Clozapine",
"{u} (Compound) resembles {v} (Compound)",
"Loxapine"
],
[
"Loxapine",
"{u} may cause a moderate... | Clozapine (Compound) resembles Loxapine (Compound) and Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that co... |
DB00015 | DB00055 | 582 | 834 | [
"DDInter1585",
"DDInter605"
] | Reteplase | Drotrecogin alfa | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids p... | Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated th... | Major | 2 | [
[
[
582,
25,
834
]
],
[
[
582,
23,
539
],
[
539,
62,
834
]
],
[
[
582,
24,
318
],
[
318,
63,
834
]
],
[
[
582,
25,
1226
],
[
1226,
6... | [
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Drotrecogin alfa"
]
],
[
[
"Reteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",... | Reteplase may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Drotrecogin alfa
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalo... |
DB06414 | DB06589 | 655 | 1,250 | [
"DDInter703",
"DDInter1400"
] | Etravirine | Pazopanib | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
655,
24,
1250
]
],
[
[
655,
6,
4973
],
[
4973,
45,
1250
]
],
[
[
655,
21,
28868
],
[
28868,
60,
1250
]
],
[
[
655,
63,
112
],
[
112,
... | [
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Etravirine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Etravirine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Pazopanib (Compound)
Etravirine (Compound) causes Stomatitis (Side Effect) and Stomatitis (Side Effect) is caused by Pazopanib (Compound)
Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Met... |
DB00620 | DB09104 | 175 | 286 | [
"DDInter1855",
"DDInter1118"
] | Triamcinolone | Magnesium hydroxide | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
175,
24,
286
]
],
[
[
175,
24,
1482
],
[
1482,
23,
286
]
],
[
[
175,
63,
88
],
[
88,
23,
286
]
],
[
[
175,
62,
1018
],
[
1018,
2... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
... | Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol... |
DB00620 | DB01400 | 175 | 1,372 | [
"DDInter1855",
"DDInter1279"
] | Triamcinolone | Neostigmine | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. | Moderate | 1 | [
[
[
175,
24,
1372
]
],
[
[
175,
63,
751
],
[
751,
40,
1372
]
],
[
[
175,
24,
61
],
[
61,
24,
1372
]
],
[
[
175,
6,
10558
],
[
10558,
... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neostigmine"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pyridostigmine"
... | Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Pyridostigmine and Pyridostigmine (Compound) resembles Neostigmine (Compound)
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Edrophonium and Edrophonium may cause a moderate inter... |
DB00749 | DB01097 | 59 | 1,377 | [
"DDInter699",
"DDInter1033"
] | Etodolac | Leflunomide | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
59,
25,
1377
]
],
[
[
59,
6,
6017
],
[
6017,
45,
1377
]
],
[
[
59,
21,
29062
],
[
29062,
60,
1377
]
],
[
[
59,
64,
126
],
[
126,
... | [
[
[
"Etodolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Etodolac",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Leflunomid... | Etodolac (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Leflunomide (Compound)
Etodolac (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Effect) is caused by Leflunomide (Compound)
Etodolac may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.